US20200345854A1 - Bispecific antibody capable of being combined with immune cells to enhance tumor killing capability, and preparation method therefor and application thereof - Google Patents
Bispecific antibody capable of being combined with immune cells to enhance tumor killing capability, and preparation method therefor and application thereof Download PDFInfo
- Publication number
- US20200345854A1 US20200345854A1 US16/935,679 US202016935679A US2020345854A1 US 20200345854 A1 US20200345854 A1 US 20200345854A1 US 202016935679 A US202016935679 A US 202016935679A US 2020345854 A1 US2020345854 A1 US 2020345854A1
- Authority
- US
- United States
- Prior art keywords
- cancer
- cell
- antigen
- nanomaterial
- antigen expressed
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- 210000002865 immune cell Anatomy 0.000 title abstract description 19
- 230000005909 tumor killing Effects 0.000 title abstract description 8
- 238000000034 method Methods 0.000 claims abstract description 21
- 210000004027 cell Anatomy 0.000 claims description 78
- 239000002086 nanomaterial Substances 0.000 claims description 75
- 239000000427 antigen Substances 0.000 claims description 49
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 41
- 108091007433 antigens Proteins 0.000 claims description 41
- 102000036639 antigens Human genes 0.000 claims description 41
- 206010028980 Neoplasm Diseases 0.000 claims description 40
- -1 polybutylene Polymers 0.000 claims description 36
- 201000011510 cancer Diseases 0.000 claims description 19
- 239000000203 mixture Substances 0.000 claims description 17
- 229920001610 polycaprolactone Polymers 0.000 claims description 16
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims description 15
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims description 15
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 15
- 239000004626 polylactic acid Substances 0.000 claims description 15
- 210000003162 effector t lymphocyte Anatomy 0.000 claims description 14
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 12
- 229920001577 copolymer Polymers 0.000 claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 8
- 206010005003 Bladder cancer Diseases 0.000 claims description 8
- 102100032937 CD40 ligand Human genes 0.000 claims description 8
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 8
- 206010009944 Colon cancer Diseases 0.000 claims description 8
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 8
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims description 8
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 8
- 206010038389 Renal cancer Diseases 0.000 claims description 8
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims description 8
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 8
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 8
- 230000004913 activation Effects 0.000 claims description 8
- 201000010881 cervical cancer Diseases 0.000 claims description 8
- 201000010982 kidney cancer Diseases 0.000 claims description 8
- 201000007270 liver cancer Diseases 0.000 claims description 8
- 208000014018 liver neoplasm Diseases 0.000 claims description 8
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 8
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 8
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 8
- 206010006187 Breast cancer Diseases 0.000 claims description 7
- 208000026310 Breast neoplasm Diseases 0.000 claims description 7
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 claims description 7
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 claims description 7
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims description 7
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims description 7
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 claims description 6
- 108010029697 CD40 Ligand Proteins 0.000 claims description 6
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 claims description 6
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 claims description 6
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims description 6
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims description 6
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims description 6
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims description 6
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 claims description 6
- 101000934341 Homo sapiens T-cell surface glycoprotein CD5 Proteins 0.000 claims description 6
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 claims description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims description 6
- 206010060862 Prostate cancer Diseases 0.000 claims description 6
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 6
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims description 6
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 claims description 6
- 102100025244 T-cell surface glycoprotein CD5 Human genes 0.000 claims description 6
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 6
- 229920000767 polyaniline Polymers 0.000 claims description 6
- 229920001748 polybutylene Polymers 0.000 claims description 6
- 239000004632 polycaprolactone Substances 0.000 claims description 6
- 229920000515 polycarbonate Polymers 0.000 claims description 6
- 239000004417 polycarbonate Substances 0.000 claims description 6
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 6
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 5
- 101150013553 CD40 gene Proteins 0.000 claims description 5
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 5
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 5
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 5
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 5
- 101100346932 Mus musculus Muc1 gene Proteins 0.000 claims description 5
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 5
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 5
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 5
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 5
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 5
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 5
- 230000001154 acute effect Effects 0.000 claims description 5
- 208000020990 adrenal cortex carcinoma Diseases 0.000 claims description 5
- 208000007128 adrenocortical carcinoma Diseases 0.000 claims description 5
- 201000011199 bladder lymphoma Diseases 0.000 claims description 5
- 230000001684 chronic effect Effects 0.000 claims description 5
- 201000004101 esophageal cancer Diseases 0.000 claims description 5
- 206010017758 gastric cancer Diseases 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 5
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 5
- 201000011549 stomach cancer Diseases 0.000 claims description 5
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims description 4
- 102100034608 Angiopoietin-2 Human genes 0.000 claims description 4
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims description 4
- 102100032912 CD44 antigen Human genes 0.000 claims description 4
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 claims description 4
- 102100025473 Carcinoembryonic antigen-related cell adhesion molecule 6 Human genes 0.000 claims description 4
- 102100034231 Cell surface A33 antigen Human genes 0.000 claims description 4
- 108010062540 Chorionic Gonadotropin Proteins 0.000 claims description 4
- 102000011022 Chorionic Gonadotropin Human genes 0.000 claims description 4
- 102100025137 Early activation antigen CD69 Human genes 0.000 claims description 4
- 102100031940 Epithelial cell adhesion molecule Human genes 0.000 claims description 4
- 102100030595 HLA class II histocompatibility antigen gamma chain Human genes 0.000 claims description 4
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 claims description 4
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims description 4
- 101000924533 Homo sapiens Angiopoietin-2 Proteins 0.000 claims description 4
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims description 4
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims description 4
- 101000914326 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 6 Proteins 0.000 claims description 4
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 claims description 4
- 101000996823 Homo sapiens Cell surface A33 antigen Proteins 0.000 claims description 4
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 claims description 4
- 101001082627 Homo sapiens HLA class II histocompatibility antigen gamma chain Proteins 0.000 claims description 4
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 claims description 4
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 claims description 4
- 101000853002 Homo sapiens Interleukin-25 Proteins 0.000 claims description 4
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims description 4
- 101000991061 Homo sapiens MHC class I polypeptide-related sequence B Proteins 0.000 claims description 4
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims description 4
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 claims description 4
- 101001128431 Homo sapiens Myeloid-derived growth factor Proteins 0.000 claims description 4
- 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 claims description 4
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 4
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 claims description 4
- 101000955962 Homo sapiens Vacuolar protein sorting-associated protein 51 homolog Proteins 0.000 claims description 4
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 claims description 4
- 102100037852 Insulin-like growth factor I Human genes 0.000 claims description 4
- 108090001005 Interleukin-6 Proteins 0.000 claims description 4
- 102000004889 Interleukin-6 Human genes 0.000 claims description 4
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 claims description 4
- 102100030301 MHC class I polypeptide-related sequence A Human genes 0.000 claims description 4
- 102100030300 MHC class I polypeptide-related sequence B Human genes 0.000 claims description 4
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims description 4
- 102100023123 Mucin-16 Human genes 0.000 claims description 4
- 108010012255 Neural Cell Adhesion Molecule L1 Proteins 0.000 claims description 4
- 102100024964 Neural cell adhesion molecule L1 Human genes 0.000 claims description 4
- 102100025131 T-cell differentiation antigen CD6 Human genes 0.000 claims description 4
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 4
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 claims description 4
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 claims description 4
- 108010087914 epidermal growth factor receptor VIII Proteins 0.000 claims description 4
- 229940084986 human chorionic gonadotropin Drugs 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 101001005269 Arabidopsis thaliana Ceramide synthase 1 LOH3 Proteins 0.000 claims description 3
- 101001005312 Arabidopsis thaliana Ceramide synthase LOH1 Proteins 0.000 claims description 3
- 102100028801 Calsyntenin-1 Human genes 0.000 claims description 3
- 101150029707 ERBB2 gene Proteins 0.000 claims description 3
- 101000633784 Homo sapiens SLAM family member 7 Proteins 0.000 claims description 3
- 101000934376 Homo sapiens T-cell differentiation antigen CD6 Proteins 0.000 claims description 3
- 108020003285 Isocitrate lyase Proteins 0.000 claims description 3
- 101000668858 Spinacia oleracea 30S ribosomal protein S1, chloroplastic Proteins 0.000 claims description 3
- 101000898746 Streptomyces clavuligerus Clavaminate synthase 1 Proteins 0.000 claims description 3
- 230000000295 complement effect Effects 0.000 claims description 3
- 239000010445 mica Substances 0.000 claims description 3
- 229910052618 mica group Inorganic materials 0.000 claims description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 2
- WEYNBWVKOYCCQT-UHFFFAOYSA-N 1-(3-chloro-4-methylphenyl)-3-{2-[({5-[(dimethylamino)methyl]-2-furyl}methyl)thio]ethyl}urea Chemical compound O1C(CN(C)C)=CC=C1CSCCNC(=O)NC1=CC=C(C)C(Cl)=C1 WEYNBWVKOYCCQT-UHFFFAOYSA-N 0.000 claims description 2
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 claims description 2
- 108091007505 ADAM17 Proteins 0.000 claims description 2
- 102000013563 Acid Phosphatase Human genes 0.000 claims description 2
- 108010051457 Acid Phosphatase Proteins 0.000 claims description 2
- 101710137115 Adenylyl cyclase-associated protein 1 Proteins 0.000 claims description 2
- 102100035248 Alpha-(1,3)-fucosyltransferase 4 Human genes 0.000 claims description 2
- 102100032959 Alpha-actinin-4 Human genes 0.000 claims description 2
- 101710115256 Alpha-actinin-4 Proteins 0.000 claims description 2
- 102000052587 Anaphase-Promoting Complex-Cyclosome Apc3 Subunit Human genes 0.000 claims description 2
- 108700004606 Anaphase-Promoting Complex-Cyclosome Apc3 Subunit Proteins 0.000 claims description 2
- 102100022716 Atypical chemokine receptor 3 Human genes 0.000 claims description 2
- 102100035526 B melanoma antigen 1 Human genes 0.000 claims description 2
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 claims description 2
- 102100032412 Basigin Human genes 0.000 claims description 2
- 102100037086 Bone marrow stromal antigen 2 Human genes 0.000 claims description 2
- 102100021943 C-C motif chemokine 2 Human genes 0.000 claims description 2
- 101710155857 C-C motif chemokine 2 Proteins 0.000 claims description 2
- 102100032367 C-C motif chemokine 5 Human genes 0.000 claims description 2
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims description 2
- 102100039398 C-X-C motif chemokine 2 Human genes 0.000 claims description 2
- 102100028666 C-type lectin domain family 4 member G Human genes 0.000 claims description 2
- 108700012439 CA9 Proteins 0.000 claims description 2
- 102100024217 CAMPATH-1 antigen Human genes 0.000 claims description 2
- 102100024209 CD177 antigen Human genes 0.000 claims description 2
- 108010065524 CD52 Antigen Proteins 0.000 claims description 2
- 102100022002 CD59 glycoprotein Human genes 0.000 claims description 2
- 102100025221 CD70 antigen Human genes 0.000 claims description 2
- 102100035793 CD83 antigen Human genes 0.000 claims description 2
- 101150108242 CDC27 gene Proteins 0.000 claims description 2
- 101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 claims description 2
- 101100005789 Caenorhabditis elegans cdk-4 gene Proteins 0.000 claims description 2
- 241000282836 Camelus dromedarius Species 0.000 claims description 2
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 claims description 2
- 102100039510 Cancer/testis antigen 2 Human genes 0.000 claims description 2
- 102100025470 Carcinoembryonic antigen-related cell adhesion molecule 8 Human genes 0.000 claims description 2
- 102100026548 Caspase-8 Human genes 0.000 claims description 2
- 108090000538 Caspase-8 Proteins 0.000 claims description 2
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 claims description 2
- 108010055166 Chemokine CCL5 Proteins 0.000 claims description 2
- 102100035954 Choline transporter-like protein 2 Human genes 0.000 claims description 2
- 102100039361 Chondrosarcoma-associated gene 2/3 protein Human genes 0.000 claims description 2
- 102100025680 Complement decay-accelerating factor Human genes 0.000 claims description 2
- 102100032768 Complement receptor type 2 Human genes 0.000 claims description 2
- 108010009392 Cyclin-Dependent Kinase Inhibitor p16 Proteins 0.000 claims description 2
- 102100024458 Cyclin-dependent kinase inhibitor 2A Human genes 0.000 claims description 2
- 102100026234 Cytokine receptor common subunit gamma Human genes 0.000 claims description 2
- 101710116148 DNA N-6-adenine-methyltransferase Proteins 0.000 claims description 2
- 101100216227 Dictyostelium discoideum anapc3 gene Proteins 0.000 claims description 2
- 102100031111 Disintegrin and metalloproteinase domain-containing protein 17 Human genes 0.000 claims description 2
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims description 2
- 108090000382 Fibroblast growth factor 6 Proteins 0.000 claims description 2
- 102100028075 Fibroblast growth factor 6 Human genes 0.000 claims description 2
- 102100037362 Fibronectin Human genes 0.000 claims description 2
- 108010067306 Fibronectins Proteins 0.000 claims description 2
- 102100021260 Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 Human genes 0.000 claims description 2
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims description 2
- 108010058597 HLA-DR Antigens Proteins 0.000 claims description 2
- 102000006354 HLA-DR Antigens Human genes 0.000 claims description 2
- 108010067802 HLA-DR alpha-Chains Proteins 0.000 claims description 2
- 101001022185 Homo sapiens Alpha-(1,3)-fucosyltransferase 4 Proteins 0.000 claims description 2
- 101000678890 Homo sapiens Atypical chemokine receptor 3 Proteins 0.000 claims description 2
- 101000874316 Homo sapiens B melanoma antigen 1 Proteins 0.000 claims description 2
- 101000798441 Homo sapiens Basigin Proteins 0.000 claims description 2
- 101000740785 Homo sapiens Bone marrow stromal antigen 2 Proteins 0.000 claims description 2
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims description 2
- 101000766915 Homo sapiens C-type lectin domain family 4 member G Proteins 0.000 claims description 2
- 101100165850 Homo sapiens CA9 gene Proteins 0.000 claims description 2
- 101000980845 Homo sapiens CD177 antigen Proteins 0.000 claims description 2
- 101000868215 Homo sapiens CD40 ligand Proteins 0.000 claims description 2
- 101000897400 Homo sapiens CD59 glycoprotein Proteins 0.000 claims description 2
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 claims description 2
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 claims description 2
- 101100061856 Homo sapiens CXCL2 gene Proteins 0.000 claims description 2
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 claims description 2
- 101000889345 Homo sapiens Cancer/testis antigen 2 Proteins 0.000 claims description 2
- 101000914320 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 8 Proteins 0.000 claims description 2
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 claims description 2
- 101000745414 Homo sapiens Chondrosarcoma-associated gene 2/3 protein Proteins 0.000 claims description 2
- 101000856022 Homo sapiens Complement decay-accelerating factor Proteins 0.000 claims description 2
- 101000941929 Homo sapiens Complement receptor type 2 Proteins 0.000 claims description 2
- 101001055227 Homo sapiens Cytokine receptor common subunit gamma Proteins 0.000 claims description 2
- 101000920667 Homo sapiens Epithelial cell adhesion molecule Proteins 0.000 claims description 2
- 101000894906 Homo sapiens Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 Proteins 0.000 claims description 2
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims description 2
- 101001046870 Homo sapiens Hypoxia-inducible factor 1-alpha Proteins 0.000 claims description 2
- 101000878602 Homo sapiens Immunoglobulin alpha Fc receptor Proteins 0.000 claims description 2
- 101001046683 Homo sapiens Integrin alpha-L Proteins 0.000 claims description 2
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 claims description 2
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 claims description 2
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 claims description 2
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 claims description 2
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 claims description 2
- 101000599048 Homo sapiens Interleukin-6 receptor subunit alpha Proteins 0.000 claims description 2
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 claims description 2
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 claims description 2
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 claims description 2
- 101000961414 Homo sapiens Membrane cofactor protein Proteins 0.000 claims description 2
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims description 2
- 101000623900 Homo sapiens Mucin-13 Proteins 0.000 claims description 2
- 101001133081 Homo sapiens Mucin-2 Proteins 0.000 claims description 2
- 101000972284 Homo sapiens Mucin-3A Proteins 0.000 claims description 2
- 101000972286 Homo sapiens Mucin-4 Proteins 0.000 claims description 2
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims description 2
- 101001024605 Homo sapiens Next to BRCA1 gene 1 protein Proteins 0.000 claims description 2
- 101000595923 Homo sapiens Placenta growth factor Proteins 0.000 claims description 2
- 101000610551 Homo sapiens Prominin-1 Proteins 0.000 claims description 2
- 101000842302 Homo sapiens Protein-cysteine N-palmitoyltransferase HHAT Proteins 0.000 claims description 2
- 101001109419 Homo sapiens RNA-binding protein NOB1 Proteins 0.000 claims description 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 2
- 101000617130 Homo sapiens Stromal cell-derived factor 1 Proteins 0.000 claims description 2
- 101000874179 Homo sapiens Syndecan-1 Proteins 0.000 claims description 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims description 2
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 claims description 2
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims description 2
- 101000730644 Homo sapiens Zinc finger protein PLAGL2 Proteins 0.000 claims description 2
- 206010021143 Hypoxia Diseases 0.000 claims description 2
- 102100022875 Hypoxia-inducible factor 1-alpha Human genes 0.000 claims description 2
- 102100038005 Immunoglobulin alpha Fc receptor Human genes 0.000 claims description 2
- 102100022339 Integrin alpha-L Human genes 0.000 claims description 2
- 102100022338 Integrin alpha-M Human genes 0.000 claims description 2
- 102100025304 Integrin beta-1 Human genes 0.000 claims description 2
- 102100025390 Integrin beta-2 Human genes 0.000 claims description 2
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 claims description 2
- 102100026720 Interferon beta Human genes 0.000 claims description 2
- 102100037850 Interferon gamma Human genes 0.000 claims description 2
- 108010047761 Interferon-alpha Proteins 0.000 claims description 2
- 102000006992 Interferon-alpha Human genes 0.000 claims description 2
- 108090000467 Interferon-beta Proteins 0.000 claims description 2
- 108010074328 Interferon-gamma Proteins 0.000 claims description 2
- 102000013462 Interleukin-12 Human genes 0.000 claims description 2
- 108010065805 Interleukin-12 Proteins 0.000 claims description 2
- 102100020793 Interleukin-13 receptor subunit alpha-2 Human genes 0.000 claims description 2
- 102000003812 Interleukin-15 Human genes 0.000 claims description 2
- 108090000172 Interleukin-15 Proteins 0.000 claims description 2
- 102000013691 Interleukin-17 Human genes 0.000 claims description 2
- 108050003558 Interleukin-17 Proteins 0.000 claims description 2
- 102000003810 Interleukin-18 Human genes 0.000 claims description 2
- 108090000171 Interleukin-18 Proteins 0.000 claims description 2
- 108010002350 Interleukin-2 Proteins 0.000 claims description 2
- 102000000588 Interleukin-2 Human genes 0.000 claims description 2
- 102000013264 Interleukin-23 Human genes 0.000 claims description 2
- 108010065637 Interleukin-23 Proteins 0.000 claims description 2
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 claims description 2
- 102000017761 Interleukin-33 Human genes 0.000 claims description 2
- 108010067003 Interleukin-33 Proteins 0.000 claims description 2
- 108090001007 Interleukin-8 Proteins 0.000 claims description 2
- 102000004890 Interleukin-8 Human genes 0.000 claims description 2
- 108010043610 KIR Receptors Proteins 0.000 claims description 2
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 claims description 2
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 claims description 2
- 108010048043 Macrophage Migration-Inhibitory Factors Proteins 0.000 claims description 2
- 102100037791 Macrophage migration inhibitory factor Human genes 0.000 claims description 2
- 102100022430 Melanocyte protein PMEL Human genes 0.000 claims description 2
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 claims description 2
- 102100039373 Membrane cofactor protein Human genes 0.000 claims description 2
- 102100034256 Mucin-1 Human genes 0.000 claims description 2
- 102100023124 Mucin-13 Human genes 0.000 claims description 2
- 102100034263 Mucin-2 Human genes 0.000 claims description 2
- 102100022497 Mucin-3A Human genes 0.000 claims description 2
- 102100022693 Mucin-4 Human genes 0.000 claims description 2
- 108010063954 Mucins Proteins 0.000 claims description 2
- 102000015728 Mucins Human genes 0.000 claims description 2
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 claims description 2
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims description 2
- KUIFHYPNNRVEKZ-VIJRYAKMSA-N O-(N-acetyl-alpha-D-galactosaminyl)-L-threonine Chemical compound OC(=O)[C@@H](N)[C@@H](C)O[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1NC(C)=O KUIFHYPNNRVEKZ-VIJRYAKMSA-N 0.000 claims description 2
- 102000036673 PRAME Human genes 0.000 claims description 2
- 108060006580 PRAME Proteins 0.000 claims description 2
- 102100034640 PWWP domain-containing DNA repair factor 3A Human genes 0.000 claims description 2
- 108050007154 PWWP domain-containing DNA repair factor 3A Proteins 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 102100021768 Phosphoserine aminotransferase Human genes 0.000 claims description 2
- 102100035194 Placenta growth factor Human genes 0.000 claims description 2
- 102100040120 Prominin-1 Human genes 0.000 claims description 2
- 108010072866 Prostate-Specific Antigen Proteins 0.000 claims description 2
- 102100030616 Protein-cysteine N-palmitoyltransferase HHAT Human genes 0.000 claims description 2
- 102100022491 RNA-binding protein NOB1 Human genes 0.000 claims description 2
- 101000737809 Rattus norvegicus Cadherin-related family member 5 Proteins 0.000 claims description 2
- 101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 claims description 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 2
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 claims description 2
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 claims description 2
- 108091007001 SLC44A2 Proteins 0.000 claims description 2
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 claims description 2
- 101800001271 Surface protein Proteins 0.000 claims description 2
- 108010002687 Survivin Proteins 0.000 claims description 2
- 102100035721 Syndecan-1 Human genes 0.000 claims description 2
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims description 2
- 102100033082 TNF receptor-associated factor 3 Human genes 0.000 claims description 2
- 108010000449 TNF-Related Apoptosis-Inducing Ligand Receptors Proteins 0.000 claims description 2
- 102000002259 TNF-Related Apoptosis-Inducing Ligand Receptors Human genes 0.000 claims description 2
- 108010008125 Tenascin Proteins 0.000 claims description 2
- 102100038126 Tenascin Human genes 0.000 claims description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 2
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 claims description 2
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims description 2
- 102100027212 Tumor-associated calcium signal transducer 2 Human genes 0.000 claims description 2
- 206010054094 Tumour necrosis Diseases 0.000 claims description 2
- 108091008605 VEGF receptors Proteins 0.000 claims description 2
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims description 2
- 102100032571 Zinc finger protein PLAGL2 Human genes 0.000 claims description 2
- 108010026331 alpha-Fetoproteins Proteins 0.000 claims description 2
- 102000013529 alpha-Fetoproteins Human genes 0.000 claims description 2
- 230000033115 angiogenesis Effects 0.000 claims description 2
- 210000001072 colon Anatomy 0.000 claims description 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 2
- 108020005243 folate receptor Proteins 0.000 claims description 2
- 102000006815 folate receptor Human genes 0.000 claims description 2
- 108040003607 interleukin-13 receptor activity proteins Proteins 0.000 claims description 2
- 108040002039 interleukin-15 receptor activity proteins Proteins 0.000 claims description 2
- 102000008616 interleukin-15 receptor activity proteins Human genes 0.000 claims description 2
- 108040001304 interleukin-17 receptor activity proteins Proteins 0.000 claims description 2
- 102000053460 interleukin-17 receptor activity proteins Human genes 0.000 claims description 2
- 108040002014 interleukin-18 receptor activity proteins Proteins 0.000 claims description 2
- 102000008625 interleukin-18 receptor activity proteins Human genes 0.000 claims description 2
- 108040006852 interleukin-4 receptor activity proteins Proteins 0.000 claims description 2
- 108040006858 interleukin-6 receptor activity proteins Proteins 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 239000003550 marker Substances 0.000 claims description 2
- 238000012737 microarray-based gene expression Methods 0.000 claims description 2
- 238000012243 multiplex automated genomic engineering Methods 0.000 claims description 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 2
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims description 2
- 210000002307 prostate Anatomy 0.000 claims description 2
- 235000002020 sage Nutrition 0.000 claims description 2
- 101150047061 tag-72 gene Proteins 0.000 claims description 2
- 102100033627 Killer cell immunoglobulin-like receptor 3DL1 Human genes 0.000 claims 1
- 102100031789 Myeloid-derived growth factor Human genes 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 abstract description 30
- 230000002147 killing effect Effects 0.000 abstract description 21
- 210000004881 tumor cell Anatomy 0.000 abstract description 20
- 230000000694 effects Effects 0.000 abstract description 13
- 230000008685 targeting Effects 0.000 abstract description 9
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 241000282414 Homo sapiens Species 0.000 description 33
- 238000006243 chemical reaction Methods 0.000 description 21
- 238000005119 centrifugation Methods 0.000 description 19
- 239000000243 solution Substances 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 239000008367 deionised water Substances 0.000 description 13
- 229910021641 deionized water Inorganic materials 0.000 description 13
- 210000001744 T-lymphocyte Anatomy 0.000 description 12
- 239000002245 particle Substances 0.000 description 10
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 10
- 238000005406 washing Methods 0.000 description 10
- 238000002659 cell therapy Methods 0.000 description 8
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 description 7
- 241000700605 Viruses Species 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 5
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 5
- 208000011691 Burkitt lymphomas Diseases 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 238000009169 immunotherapy Methods 0.000 description 5
- 239000012046 mixed solvent Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 230000008901 benefit Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 201000006585 gastric adenocarcinoma Diseases 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000003760 magnetic stirring Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 210000001239 CD8-positive, alpha-beta cytotoxic T lymphocyte Anatomy 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 210000001985 kidney epithelial cell Anatomy 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000011580 nude mouse model Methods 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 241000203022 Acholeplasma laidlawii Species 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 241000223838 Babesia bovis Species 0.000 description 1
- 241000120506 Bluetongue virus Species 0.000 description 1
- 241000589969 Borreliella burgdorferi Species 0.000 description 1
- 241000589567 Brucella abortus Species 0.000 description 1
- 229940124292 CD20 monoclonal antibody Drugs 0.000 description 1
- 229940124293 CD30 monoclonal antibody Drugs 0.000 description 1
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 1
- 201000007336 Cryptococcosis Diseases 0.000 description 1
- 241000221204 Cryptococcus neoformans Species 0.000 description 1
- 201000003808 Cystic echinococcosis Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 208000001490 Dengue Diseases 0.000 description 1
- 206010012310 Dengue fever Diseases 0.000 description 1
- 241000244170 Echinococcus granulosus Species 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 241000228404 Histoplasma capsulatum Species 0.000 description 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 102000002698 KIR Receptors Human genes 0.000 description 1
- 241000589242 Legionella pneumophila Species 0.000 description 1
- 241000222736 Leishmania tropica Species 0.000 description 1
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 241000520674 Mesocestoides corti Species 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- 241000713333 Mouse mammary tumor virus Species 0.000 description 1
- 241000711386 Mumps virus Species 0.000 description 1
- 241000714177 Murine leukemia virus Species 0.000 description 1
- 241000711408 Murine respirovirus Species 0.000 description 1
- 241000186362 Mycobacterium leprae Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 241000204028 Mycoplasma arginini Species 0.000 description 1
- 241000202956 Mycoplasma arthritidis Species 0.000 description 1
- 241000202938 Mycoplasma hyorhinis Species 0.000 description 1
- 241000202894 Mycoplasma orale Species 0.000 description 1
- 241000202934 Mycoplasma pneumoniae Species 0.000 description 1
- 241000202889 Mycoplasma salivarium Species 0.000 description 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
- 241000588650 Neisseria meningitidis Species 0.000 description 1
- 241000243985 Onchocerca volvulus Species 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 208000034530 PLAA-associated neurodevelopmental disease Diseases 0.000 description 1
- 241000223960 Plasmodium falciparum Species 0.000 description 1
- 241000223810 Plasmodium vivax Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 241000702263 Reovirus sp. Species 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 241000710799 Rubella virus Species 0.000 description 1
- 241000242677 Schistosoma japonicum Species 0.000 description 1
- 241000242680 Schistosoma mansoni Species 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- 241000710960 Sindbis virus Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000193985 Streptococcus agalactiae Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 208000000389 T-cell leukemia Diseases 0.000 description 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
- 241001672171 Taenia hydatigena Species 0.000 description 1
- 241000244154 Taenia ovis Species 0.000 description 1
- 241000244159 Taenia saginata Species 0.000 description 1
- 241000223779 Theileria parva Species 0.000 description 1
- 241000223997 Toxoplasma gondii Species 0.000 description 1
- 241000589884 Treponema pallidum Species 0.000 description 1
- 241000243777 Trichinella spiralis Species 0.000 description 1
- 241000223104 Trypanosoma Species 0.000 description 1
- 241000223105 Trypanosoma brucei Species 0.000 description 1
- 241000223109 Trypanosoma cruzi Species 0.000 description 1
- 241000223097 Trypanosoma rangeli Species 0.000 description 1
- 241000711975 Vesicular stomatitis virus Species 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- 241000710886 West Nile virus Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 229940056450 brucella abortus Drugs 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 208000025729 dengue disease Diseases 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229940115932 legionella pneumophila Drugs 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229940096911 trichinella spiralis Drugs 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/44—Antibodies bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
- A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
- A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
- A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
- A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
- A61K47/6937—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol the polymer being PLGA, PLA or polyglycolic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2815—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Definitions
- the present invention relates to the field of immunotherapy, and particularly to a bispecific antibody capable of being combined with immune cells to enhance a targeting tumor killing capability, and a preparation method therefor and an application thereof.
- the immune cell therapy technology has undergone the development of LAK, CIK, DC-CIK and now is rapidly growing toward antigen-loading DC-induced T-cell (DiKat), genetically modified DC-induced T cells (AV/LV-DC-CTL) and genetically modified chimeric antigen receptor T cells (CAR-T).
- DC-induced T-cell DiKat
- AV/LV-DC-CTL genetically modified DC-induced T cells
- CAR-T genetically modified chimeric antigen receptor T cells
- Novartis announced a result of B lymphoma clinical trial for the CD19 target with a rate of complete efficacy of 93%, further highlighting the prospect of the immune cell therapy of cancer.
- CAR-T is challenged because of its complex cell preparation process, as well as high costs (the cost of each course is expected to be 500,000 US dollars), and currently shows a good efficacy only for CD19-positive B lymphoma, suggesting its obvious limitations.
- the present invention provides a bispecific antibody, as well as a preparation method therefor and an application thereof, and particularly a bispecific antibody capable of being combined with immune cells to enhance a targeting tumor killing capability, as well as a preparation method therefor and an application thereof.
- the present invention provides a bispecific antibody capable of being combined with immune cells to enhance a targeting tumor killing capability, said bispecific antibody comprising a first antibody moiety that binds to an antigen expressed on an effector T cell and a second antibody moiety that binds to an antigen expressed on a target cell.
- the second antibody moiety described herein may be one or more antibodies that can bind to the target cell.
- the first antibody moiety and the second antibody moiety are connected by a nanomaterial.
- the connection can be made by using the carboxyl group of the nanoparticle surface and the amino group of the antibody.
- a “multispecific antibody” is an antibody that may simultaneously bind to at least two targets with different structures (e.g., two different antigens, two different epitopes on the same antigen, or a hapten and/or antigen or epitope).
- a “bispecific antibody” is an antibody that can bind to two targets with different structures simultaneously.
- the “multispecific antibody” or “bispecific antibody” described herein includes multiple or two antibodies (e.g., two monoclonal antibodies) that are connected by a nanomaterial and bind to different targets.
- the multispecific antibody or bispecific antibody described herein may have at least one antibody that specifically binds to a T cell and at least one antibody that specifically binds to an antigen produced by a diseased cell, tissue, organ or pathogen, or an antigen related thereto (e.g., a tumor-associated antigen), which antibodies are connected by a nanomaterial.
- an antigen produced by a diseased cell, tissue, organ or pathogen, or an antigen related thereto e.g., a tumor-associated antigen
- the present invention utilizes the specific binding ability of an antibody to attach the antibodies capable of specifically recognizing a tumor cell and a tumor killer cell to a clinically available degradable nanomaterial, so as to form a bispecific antibody.
- most anti-cancer monoclonal antibodies as a drug for the treatment of diseases are mainly based on their inherent biological functions, including complement-mediated cytotoxicity (CDC), antibody-dependent cell-mediated cytotoxicity (ADCC), apoptosis induction, opsonophagocytosis etc.
- the bispecific antibody of the invention not only specifically recognizes and binds to a tumor cell, but also recognizes and binds to a killer T lymphocyte, thereby assisting the T cell to recognize the tumor cell and narrowing the physical distance between the tumor cell and the killer T lymphocyte, and thus facilitating the killing of the tumor cell by the T lymphocyte. Accordingly, the specificity and effectiveness of immune cell therapy are strengthened.
- the nanomaterial described herein is a biodegradable nanomaterial.
- the nanomaterial described herein is generally present in the form of nanoparticle, which is selected from a conventional degradable nanomaterial, such as any of polylactic acid-glycolic acid, polylactic acid, polycaprolactone, polybutylene glycol succinate, polyaniline, polycarbonate, glycolide-lactide copolymer or glycolide-caprolactone copolymer, or a mixture thereof, preferably, but not limited to these.
- a conventional degradable nanomaterial such as any of polylactic acid-glycolic acid, polylactic acid, polycaprolactone, polybutylene glycol succinate, polyaniline, polycarbonate, glycolide-lactide copolymer or glycolide-caprolactone copolymer, or a mixture thereof, preferably, but not limited to these.
- PLGA is a pharmaceutical excipient approved by FDA, which has good biocompatibility and biodegradability, no toxicity and irritation, high strength and is easily processed and molded. It is finally decomposed into hydrated carbon dioxide by enzymatically hydrolysis in vivo, and can be completely absorbed within 3-6 months after being implanted into the body.
- the target cell is B cell, cancer cell, or pathogen cell, etc.
- the antigen expressed on the target cell is any one of carbonic anhydrase IX, alpha-fetoprotein, alpha-actinin-4, A3, A33 antibody-specific antigen, ANG2, ART-4, B7, Ba 733, BAGE, BrE3-antigen, CA125, CAMEL, CAP-1, CASP-8/m, CCCL19, CCCL21, CD1, CD1a, CD2, CD3, CD4, CD5, CD8, CD11A, CD14, CD15, CD16, CD18, CD19, CD20, CD21, CD22, CD23, CD25, CD29, CD30, CD32b, CD33, CD37, CD38, CD40, CD40L, CD45, CD46, CD52, CD54, CD55, CD59, CD64, CD66a-e, CD67, CD70, CD70L, CD74, CD79a, CD79b, CD80, CD83, CD95, CD126, CD132, CD133, CD138, CD147, CD154,
- hyorhinis M. orale, M. arginini, Acholeplasma laidlawii, M. salivarium and M. pneumoniae , preferably any one of CD19, CD20, CD22, CD30, CD33, CD38, CD123, Muc1, Muc16, HER2, HERS, EGFRvIII, VEGFA, CEA, GPA33, GP100, ANG2, L1CAM, ROR-1, CS1, MICA or MICB.
- the antigen expressed on the effector T cell is any one of ADAM17, CD2, CD3, CD4, CD5, CD6, CD8, CD11a, CD11b, CD14, CD16, CD16b, CD25, CD28, CD30, CD32a, CD40, CD40L, CD44, CD45, CD56, CD57, CD64, CD69, CD74, CD89, CD90, CD137, CD177, CEACAM6, CEACAM8, HLA-DRa chain, KIR, LSECtin or SLC44A2, preferably any one of CD2, CD3, CD4, CD5, CD6, CD8, CD25, CD28, CD30, CD40, CD40L, CD44, CD45, CD69 or CD90.
- the present invention also provides a method of producing a bispecific antibody as described in the first aspect of the invention comprising connecting the nanomaterial to the first antibody moiety and the second antibody moiety.
- the method for producing a bispecific antibody according to the present invention comprises the steps of:
- the preparation of the nanomaterial comprises: dissolving the nanomaterial completely by a solvent, stirring and adding water to form a uniform emulsion.
- the nanomaterial is any one of polylactic acid-glycolic acid, polylactic acid, polycaprolactone, polybutylene glycol succinate, polyaniline, polycarbonate, glycolide-lactide copolymer or glycolide-caprolactone copolymer, or a mixture thereof.
- the solvent is any one of acetone, butanone, methanol, ethanol or isopropanol, or a mixture thereof.
- the collection of the nanomaterial comprises: collecting the prepared nanomaterial by centrifugation, and then washing the nanomaterial by resuspending in deionized water twice.
- the activation of the nanomaterial comprises: activating the nanomaterial for 0.5-5 hours by using a mixed solvent of 1-10 mg/mL 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDS) and N-hydroxysuccinimide (NHS) at room temperature.
- EDS 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride
- NHS N-hydroxysuccinimide
- the connection comprises: collecting the activated nanomaterial by centrifugation, and then washing the nanomaterial once with the connecting reaction solution, adding a mixture of the first antibody moiety and the second antibody moiety to be connected in an equal volume into the connecting reaction solution, and then resuspending the nanomaterial with the connecting reaction solution containing the first antibody moiety and the second antibody moiety and conducting the connecting reaction for 0.5-5 hours at room temperature.
- the nanomaterial is collected by centrifugation.
- the nanomaterial is washed twice in Dulbecco's phosphate buffer saline (D-PBS), and then resuspended in D-PBS and stored at 4° C.
- D-PBS Dulbecco's phosphate buffer saline
- the method for producing bispecific antibodies described herein comprises the following steps:
- the present invention also provides the use of the bispecific antibody as described in the first aspect in the manufacture of a medicament for the treatment, prevention or diagnosis of a tumor.
- the tumor includes, but not limited to, liver cancer, non-small cell lung cancer, small cell lung cancer, adrenocortical carcinoma, acute (chronic B) lymphocytoma, myeloma, prostate cancer, breast cancer, esophageal cancer, gastric cancer, colorectal cancer, cervical cancer, kidney cancer, bladder cancer and lymphoma.
- the present invention also provides the bispecific antibody according to any one of claims 1 to 3 for use in the treatment or prevention of a tumor.
- the tumor includes, but not limited to, liver cancer, non-small cell lung cancer, small cell lung cancer, adrenocortical carcinoma, acute (chronic B) lymphocytoma, myeloma, prostate cancer, breast cancer, esophageal cancer, gastric cancer, colorectal cancer, cervical cancer, kidney cancer, bladder cancer and lymphoma.
- the present invention provides a method of treating a tumor comprising administering to a subject the bispecific antibody of the invention.
- the tumor includes, but not limited to, liver cancer, non-small cell lung cancer, small cell lung cancer, adrenocortical carcinoma, acute (chronic B) lymphocytoma, myeloma, prostate cancer, breast cancer, esophageal cancer, gastric cancer, colorectal cancer, cervical cancer, kidney cancer, bladder cancer and lymphoma.
- the invention has at least the following beneficial effects:
- the bispecific antibody according to present invention can be more quickly, simply and practically produced as compared to the existing bispecific antibodies which are expressed by biological methods.
- the bispecific antibody according to present invention can be connected directly to the monoclonal antibodies approved on the market. Because the raw materials to be used are all clinically approved on the market, the bispecific antibody prepared according to the invention can quickly enter clinical use;
- the bispecific antibody of the present invention has disadvantages such as biodegradability, no gene recombination, low side effect, high safety, low cost, capability to combine respective specific antibodies for various tumor cells, ease of use, etc.
- a similar effect on targeting and efficiently killing cancer cells can be achieved by administrating the bispecific antibody preparation of the present invention to a subject while returning the CTL cells induced in vitro to the subject via infusion.
- the resulted side effects are lower than CAR-T therapy; (3) All of the materials of the present invention can be degraded into non-toxic and harmless products in the human body and can be degraded and metabolized shortly. Accordingly, the present invention is safer than CAR-T.
- FIG. 1 shows assembling of the bispecific antibody of Example 1.
- FIG. 2 shows the result of the cell killing experiments of the bispecific antibody of Example 1.
- FIGS. 3-9 show the ability of other bispecific antibodies to kill tumor cells.
- FIG. 10 shows the efficacy of a bispecific antibody anti-CD3-PLGA-anti-MUC1 on inhibiting tumor in vivo.
- FIG. 11 shows the curve of laboratory animal mortality for antitumor experiments in vivo.
- FIG. 1 shows assembling of the bispecific antibody of this Example. The process comprises the following specific steps:
- PLGA was completely dissolved to a concentration of 5 mg/mL using acetone, and the solution of PLGA and acetone was added into deionized water in a volume ratio of 1:4 of acetone and deionized water with magnetic stirring at 1000 rpm/min, to form a uniform emulsion, and then continue to stir until volatilization of acetone;
- Collection of PLGA nanoparticles collecting the prepared nanoparticles with larger particle size by centrifugation at 8000 rpm/min for 10 min; then collecting the prepared nanoparticles with smaller particle size by centrifugation at 15000 rpm/min for 10 min, and then resuspended in deionized water respectively, and repeatedly washing the nanomaterials twice; nanoparticles with larger particle size and nanoparticles with smaller particle size were carried out as follows; (3) Activation of PLGA nanoparticles: using a mixed solvent of 5 mg/mL 1-ethyl-
- the results are expressed as the average ⁇ standard deviation of three independent experiments.
- the evaluation results are shown in FIG. 2 , in which * indicates a significant difference in T test.
- the A in FIG. 2 represents bispecific antibodies connected to nanoparticles with a larger particle size (i.e., particles collected by centrifugation at 8000 rpm/min for 10 min), while B represents bispecific antibodies connected to nanoparticles with a smaller particle size (i.e., particles not collected by centrifugation at 8000 rpm/min for 10 min but collected by centrifugation at 15,000 rpm/min for 10 min).
- the killing rate of the control group is 7.9%; the killing rate of the group of the bispecific antibodies connected to nanoparticles with a larger particle size is 24.5%; the killing rate of the group of the bispecific antibodies connected to nanoparticles with a smaller particle size is 40.7%.
- bispecific antibodies capable of being combined with immune cells to enhance the targeting tumor killing ability were prepared.
- the preparation process is as follows:
- PLA was completely dissolved to a concentration of 15 mg/mL using acetone, and the solution of PLA and acetone was added into deionized water in a volume ratio of 1:4 of acetone and deionized water with magnetic stirring at 500 rpm/min, to form a uniform emulsion, and then continue to stir until volatilization of acetone;
- Collection of PLA nanoparticles collecting the prepared nanoparticles by centrifugation at 8000 rpm/min, and then resuspended in deionized water, and repeatedly washing the nanomaterials twice;
- Activation of PLA nanoparticles using a mixed solvent of 1 mg/mL 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride and N-hydroxysuccinimide at room temperature to activate PLA nanopoarticles for 0.5 h;
- Connecting PLA nanoparticles to antibodies collecting the activated nanomaterials by centri
- bispecific antibodies capable of being combined with immune cells to enhance the targeting tumor killing ability was prepared.
- the preparation process is as follows:
- PCL was completely dissolved to a concentration of 30 mg/mL using acetone, and the solution of PCL and acetone was added into deionized water in a volume ratio of 1:4 of acetone and deionized water with magnetic stirring at 1500 rpm/min, to form a uniform emulsion, and then continue to stir until volatilization of acetone;
- Collection of PCL nanoparticles collecting the prepared nanoparticles by centrifugation at 15000 rpm/min, and then resuspended in deionized water, and repeatedly washing the nanomaterials twice;
- Activation of PCL nanoparticles using a mixed solvent of 10 mg/mL 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride and N-hydroxysuccinimide at room temperature to activate PCL nanopoarticles for 5 h;
- DC-CIK cells were cultured in each well for 12 h in 96-well plates and then the original medium was discarded.
- the density of DC-CIK cells was adjusted by X-vivo 15 medium without cytokine, resulting in that DC-CIK cell number in a volume of 100 ⁇ l was 4 times larger than the target cells (effect-target ratio is 4:1).
- 100 ⁇ l suspension of DC-CIK cells was added in a cancer cell culture plate, and 10 ⁇ l prepared bispecific antibody (bispecific antibody preparation content: 0.2 mg, with a total amount of monoclonal antibodies 0.2 ⁇ g) was added, incubated for 8 h in an incubator, and then CCK-8 reagent was added, incubated according to the reagent instructions.
- the absorbance at 450 nm was measured using a microplate reader.
- Statistical analysis of the data was performed, according to the following formula to calculate killing rate of DC-CIK cells on cancer cells.
- Killing rate [1 ⁇ (experimental group ⁇ effect control group)/(target control group ⁇ blank control group)] ⁇ 100%
- the blank control group represents the added medium; the target control group represents the added target cell+medium; the effect control group represents the added the effector cell+medium; the experimental group represents the effector cell+target cell+medium+bispecific antibody.
- HKC human embryo kidney epithelial cells
- A549 - human non-small cell lung cancer cells HepG2 - human liver cancer cells
- HT29 - human colon cancer cells AGS - human gastric adenocarcinoma cells
- Hela - human cervical cancer cells 5637 - human bladder cancer cells
- OS-RC-2 human kidney cancer cells.
- anti-CD3 and anti-CD33 bispecific antibodies connected via nanoparticles i.e. anti-CD3-PLGA-anti-CD33, anti-CD3-PLA-anti-CD33 and anti-CD3-PCL-anti-CD33.
- anti-CD3-PLGA-anti-CD33 anti-CD3-PLA-anti-CD33
- anti-CD3-PCL-anti-CD33 anti-CD3-PCL-anti-CD33
- the bispecific antibodies CD3-PLA-CD33 and CD3-PCL-CD33 both showed a killing rate of more than 83% for black Burkitt lymphoma cells and human B lymphocytoma cells.
- anti-CD8 and anti-MUC1 bispecific antibodies connected via nanoparticles i.e. anti-CD8-PLGA-anti-MUC1, anti-CD8-PLA-anti-MUC1 and anti-CD8-PCL-anti-MUC1, were prepared.
- anti-CD8-PLGA-anti-MUC1, anti-CD8-PLA-anti-MUC1 and anti-CD8-PCL-anti-MUC1 were prepared.
- the ability of the bispecific antibodies of the invention to kill tumor cells was evaluated according to the method described in Example 5.
- HKC human embryo kidney epithelial cells
- A549 - human non-small cell lung cancer cells HepG2 - human liver cancer cells
- HT29 - human colon cancer cells AGS - human gastric adenocarcinoma cells
- Hela - human cervical cancer cells 5637 - human bladder cancer cells
- OS-RC-2 human kidney cancer cells.
- the bispecific antibodies anti-CD8-PLA-anti-MUC1 and anti-CD8-PCL-anti-MUC1 both showed a killing rate of more than 95% for human non-small cell lung cancer cells and human gastric adenocarcinoma cells; both showed a killing rate of more than 92% for human colon cancer cells and human kidney cancer cells; both showed a killing rate of nearly 90% for human breast cancer cells, human cervical cancer cells and human bladder cancer cells; showed a killing rate of about 80% for human liver cancer cells.
- bispecific antibodies connected via nanoparticles i.e. anti-CD3-PLGA-anti-CD19, anti-CD3-PLGA-anti-CD20, anti-CD3-PLGA-anti-her2 were prepared.
- the ability of the bispecific antibodies to kill tumor cells was evaluated. The results are shown in Tables 4-7 and FIGS. 6-9 .
- the anti-tumor effect of the bispecific antibodies of the present invention were evaluated. Specifically, healthy Balb-c nude mice (clean grade, female, four weeks old, 18-22 g in weight, purchased from the Guangdong Provincial Medicine Laboratory Animal Center) were inoculated with human lung adenocarcinoma cell A549 at armpit. After 3-4 weeks of inoculation, 30 nude mice with tumor diameter of about 0.5 ⁇ 0.5 cm were randomly divided into three groups for the experiment.
- mice were administered once via the tail-intravenous injection.
- 1 ⁇ 10 6 DC-CIK cells were injected each time in the DC-CIK group; 1 ⁇ 10 6 DC-CIK cells and 0.4 mg (a total amount of monoclonal antibody 0.4 ⁇ g) bispecific antibody anti-CD3-PLGA-anti-MUC1 were each time injected in the DC-CIK+bispecific antibody group; the same volume of saline was injected in the control group.
- the tumor volume was recorded from the first day. Calculate the inhibitory rate of the bispecific antibodies against tumors.
- the average tumor volume of each group is shown in FIG. 10 .
- the results showed that the inhibitory rate of the bispecific antibody anti-CD3-PLGA-anti-MUC1 against tumors was 88.73%, and the tumors of 60% of the animals (6/10) completely disappeared.
- the bispecific antibodies of the present invention have an improved ability to kill cancer cells by T cells, can be combined with the immune cells to enhance tumor killing ability, and have advantages such as less side effects, higher safety, lower cost, easy to use and so on as compared to CAR-T immune cell therapy.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Nanotechnology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Mycology (AREA)
- Gynecology & Obstetrics (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
Abstract
Description
- This application is a continuation of U.S. patent application Ser. No. 15/548,630, filed Aug. 3, 2017, which is a 371 of International Patent Application No. PCT/CN2016/079307 filed on Apr. 14, 2016, the entire content and disclosure of each is incorporated herein by reference.
- The present invention relates to the field of immunotherapy, and particularly to a bispecific antibody capable of being combined with immune cells to enhance a targeting tumor killing capability, and a preparation method therefor and an application thereof.
- In 2008, New England Journal of Medicine reported that one case of immunotherapy on advanced melanoma was successful, and the patient had developed multiple metastases in the body, all of which disappeared after autologous CD4+ T cell treatment, with 26 months of long-term survival via a follow-up. In 2010, FDA approved autologous immune cell therapy technology of Dendreon Corporation for the clinical application of prostate cancer, and in 2011, three scientists engaged in cancer immunotherapy also was awarded Nobel Prize for medicine, suggesting a broad prospect of immunotherapy in malignant treatment.
- In recent years, the use of genetically modified and induced T cell immunotherapy has achieved good results on tumor, which points out a new direction for developing immune cell therapy of tumor. This suggests a broad prospect of immunotherapy in malignant treatment.
- The immune cell therapy technology has undergone the development of LAK, CIK, DC-CIK and now is rapidly growing toward antigen-loading DC-induced T-cell (DiKat), genetically modified DC-induced T cells (AV/LV-DC-CTL) and genetically modified chimeric antigen receptor T cells (CAR-T). Currently, Novartis announced a result of B lymphoma clinical trial for the CD19 target with a rate of complete efficacy of 93%, further highlighting the prospect of the immune cell therapy of cancer. However, CAR-T is challenged because of its complex cell preparation process, as well as high costs (the cost of each course is expected to be 500,000 US dollars), and currently shows a good efficacy only for CD19-positive B lymphoma, suggesting its obvious limitations.
- An urgent need exists for solving the problem on how to develop an immune cell therapy technology, which has enhanced specificity and effectiveness and the advantages of simple and convenient use etc.
- The present invention provides a bispecific antibody, as well as a preparation method therefor and an application thereof, and particularly a bispecific antibody capable of being combined with immune cells to enhance a targeting tumor killing capability, as well as a preparation method therefor and an application thereof.
- To this end, the present invention adopts the following technical solutions:
- In a first aspect, the present invention provides a bispecific antibody capable of being combined with immune cells to enhance a targeting tumor killing capability, said bispecific antibody comprising a first antibody moiety that binds to an antigen expressed on an effector T cell and a second antibody moiety that binds to an antigen expressed on a target cell.
- The second antibody moiety described herein may be one or more antibodies that can bind to the target cell.
- In the present invention, the first antibody moiety and the second antibody moiety are connected by a nanomaterial. The connection can be made by using the carboxyl group of the nanoparticle surface and the amino group of the antibody.
- A “multispecific antibody” is an antibody that may simultaneously bind to at least two targets with different structures (e.g., two different antigens, two different epitopes on the same antigen, or a hapten and/or antigen or epitope). A “bispecific antibody” is an antibody that can bind to two targets with different structures simultaneously. The “multispecific antibody” or “bispecific antibody” described herein includes multiple or two antibodies (e.g., two monoclonal antibodies) that are connected by a nanomaterial and bind to different targets. The multispecific antibody or bispecific antibody described herein may have at least one antibody that specifically binds to a T cell and at least one antibody that specifically binds to an antigen produced by a diseased cell, tissue, organ or pathogen, or an antigen related thereto (e.g., a tumor-associated antigen), which antibodies are connected by a nanomaterial.
- For the purpose of immune cell targeting therapy, the present invention utilizes the specific binding ability of an antibody to attach the antibodies capable of specifically recognizing a tumor cell and a tumor killer cell to a clinically available degradable nanomaterial, so as to form a bispecific antibody. In contrast, most anti-cancer monoclonal antibodies as a drug for the treatment of diseases are mainly based on their inherent biological functions, including complement-mediated cytotoxicity (CDC), antibody-dependent cell-mediated cytotoxicity (ADCC), apoptosis induction, opsonophagocytosis etc. The bispecific antibody of the invention not only specifically recognizes and binds to a tumor cell, but also recognizes and binds to a killer T lymphocyte, thereby assisting the T cell to recognize the tumor cell and narrowing the physical distance between the tumor cell and the killer T lymphocyte, and thus facilitating the killing of the tumor cell by the T lymphocyte. Accordingly, the specificity and effectiveness of immune cell therapy are strengthened.
- The nanomaterial described herein is a biodegradable nanomaterial.
- The nanomaterial described herein is generally present in the form of nanoparticle, which is selected from a conventional degradable nanomaterial, such as any of polylactic acid-glycolic acid, polylactic acid, polycaprolactone, polybutylene glycol succinate, polyaniline, polycarbonate, glycolide-lactide copolymer or glycolide-caprolactone copolymer, or a mixture thereof, preferably, but not limited to these.
- The nanomaterial used herein possesses the advantages of slow releasing and good biocompatibility etc. For example, PLGA is a pharmaceutical excipient approved by FDA, which has good biocompatibility and biodegradability, no toxicity and irritation, high strength and is easily processed and molded. It is finally decomposed into hydrated carbon dioxide by enzymatically hydrolysis in vivo, and can be completely absorbed within 3-6 months after being implanted into the body.
- In the present invention, the target cell is B cell, cancer cell, or pathogen cell, etc.
- Preferably, the antigen expressed on the target cell is any one of carbonic anhydrase IX, alpha-fetoprotein, alpha-actinin-4, A3, A33 antibody-specific antigen, ANG2, ART-4, B7, Ba 733, BAGE, BrE3-antigen, CA125, CAMEL, CAP-1, CASP-8/m, CCCL19, CCCL21, CD1, CD1a, CD2, CD3, CD4, CD5, CD8, CD11A, CD14, CD15, CD16, CD18, CD19, CD20, CD21, CD22, CD23, CD25, CD29, CD30, CD32b, CD33, CD37, CD38, CD40, CD40L, CD45, CD46, CD52, CD54, CD55, CD59, CD64, CD66a-e, CD67, CD70, CD70L, CD74, CD79a, CD79b, CD80, CD83, CD95, CD126, CD132, CD133, CD138, CD147, CD154, CDC27, CDK-4/m, CDKN2A, CS1, CXCR4, CXCR7, CXCL12, HIF-1alpha, colon-specific antigen-p (CSAp), CEA(CEACAM5), CEACAM6, c-met, DAM, EGFR, EGFRvIII, EGP-1, EGP-2, ELF2-M, Ep-CAM, Flt-1, Flt-3, folate receptor, G250 antigen, GAGE, gp100, GPA33, GROB, HLA-DR, HM1.24, human chorionic gonadotropin (HCG) and its subunit, HER2/neu, HER3, HMGB-1, hypoxia-inducible factor (HIF-1), HSP70-2M, HST-2, Ia, IGF-1R, IFN-γ, IFN-α, IFN-β, IL-2, IL-4R, IL-6R, IL-13R, IL-15R, IL-17R, IL-18R, IL-6, IL-8, IL-12, IL-15, IL-17, IL-18, IL-23, IL-25, IL-33, insulin-like growth factor-1 (IGF-1), KC4-antigen, KS-1-antigen, KS1-4, L1CAM, Le-Y, LDR/FUT, macrophage migration inhibitory factor (MIF), MAGE, MAGE-3, MART-1, MART-2, NY-ESO-1, TRAG-3, mCRP, MCP-1, MICA, MICB, MIP-1A, MIP-1B, MIF, MUC1, MUC2, MUC3, MUC4, MUC5ac, MUC13, MUC16, MUM-1/2, MUM-3, NCA66, NCA95, NCA90, pancreatic cancer mucin, placental growth factor, p53, PLAGL2, prostate acid phosphatase, PSA, PRAME, PSMA, P1GF, ILGF, ILGF-1R, IL-6, IL-25, ROR-1, RS5, RANTES, T101, SAGE, 5100, survivin, survivin-2B, TAC, TAG-72, tenascin, TRAIL receptor, TNF-alpha, Tn antigen, Thomson-Friedrich antigen, tumor necrosis antigen, TROP-2, VEGFA, VEGFR, ED-B fibronectin, WT-1, 17-1A-antigen, complement factor C3, C3a, C3b, C5a, C5, angiogenesis marker, bc1-2, bc1-6, Kras, cMET, oncogene product, HIV virus, Mycobacterium tuberculosis, Streptococcus agalactiae, meticillin-resistant Staphylococcus aureus, Legionella pneumophila, Streptococcus pyogenes, Escherichia coli, Neisseria gonorrhoeae, Neisseria meningitidis, Pneumococcus, Cryptococcus neoformans, Histoplasma capsulatum, Hemophilis influenzae B, Treponema pallidum, Lyme disease spirochetes, Pseudomonas aeruginosa, Mycobacterium leprae, Brucella abortus, Rabies virus, Influenza virus, Cytomegalovirus, Type I herpes simplex virus, type II herpes simplex virus, human serum parvo-like virus, respiratory syncytial virus, varicella-zoster virus, hepatitis B virus, hepatitis C virus, measles virus, adenovirus, human T cell leukemia virus, Epstein-Barr virus, murine leukemia virus, mumps virus, vesicular stomatitis virus, Sindbis virus, lymphocyte choriomeningitis virus, Wart virus, Blue tongue virus, Sendai virus, Cat leukemia virus, Reovirus, Poliovirus, Simian
virus 40, mouse mammary tumor virus, Dengue fever virus, rubella virus, West Nile virus, Plasmodium falciparum, Plasmodium vivax, Toxoplasma gondii, Trypanosoma rangeli, Trypanosoma cruzi, Trypanosoma rhodesiensei, Trypanosoma brucei, Schistosoma mansoni, Schistosoma japonicum, Babesia bovis, Elmeria tenella, Onchocerca volvulus, Leishmania tropica, Trichinella spiralis, Theileria parva, Taenia hydatigena, Taenia ovis, Taenia saginata, Echinococcus granulosus, Mesocestoides corti, Mycoplasma arthritidis, M. hyorhinis, M. orale, M. arginini, Acholeplasma laidlawii, M. salivarium and M. pneumoniae, preferably any one of CD19, CD20, CD22, CD30, CD33, CD38, CD123, Muc1, Muc16, HER2, HERS, EGFRvIII, VEGFA, CEA, GPA33, GP100, ANG2, L1CAM, ROR-1, CS1, MICA or MICB. - Preferably, the antigen expressed on the effector T cell is any one of ADAM17, CD2, CD3, CD4, CD5, CD6, CD8, CD11a, CD11b, CD14, CD16, CD16b, CD25, CD28, CD30, CD32a, CD40, CD40L, CD44, CD45, CD56, CD57, CD64, CD69, CD74, CD89, CD90, CD137, CD177, CEACAM6, CEACAM8, HLA-DRa chain, KIR, LSECtin or SLC44A2, preferably any one of CD2, CD3, CD4, CD5, CD6, CD8, CD25, CD28, CD30, CD40, CD40L, CD44, CD45, CD69 or CD90.
- In a second aspect, the present invention also provides a method of producing a bispecific antibody as described in the first aspect of the invention comprising connecting the nanomaterial to the first antibody moiety and the second antibody moiety.
- The method for producing a bispecific antibody according to the present invention comprises the steps of:
- (1) preparation, collection and activation of a nanomaterial;
(2) connecting the nanomaterial obtained in step (1) with a mixture of the first antibody moiety and the second antibody moiety. - In the step (1) of the invention, the preparation of the nanomaterial comprises: dissolving the nanomaterial completely by a solvent, stirring and adding water to form a uniform emulsion.
- Preferably, the nanomaterial is any one of polylactic acid-glycolic acid, polylactic acid, polycaprolactone, polybutylene glycol succinate, polyaniline, polycarbonate, glycolide-lactide copolymer or glycolide-caprolactone copolymer, or a mixture thereof.
- Preferably, the solvent is any one of acetone, butanone, methanol, ethanol or isopropanol, or a mixture thereof.
- Preferably, the collection of the nanomaterial comprises: collecting the prepared nanomaterial by centrifugation, and then washing the nanomaterial by resuspending in deionized water twice.
- Preferably, the activation of the nanomaterial comprises: activating the nanomaterial for 0.5-5 hours by using a mixed solvent of 1-10 mg/mL 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDS) and N-hydroxysuccinimide (NHS) at room temperature.
- In the step (2) of the invention, the connection comprises: collecting the activated nanomaterial by centrifugation, and then washing the nanomaterial once with the connecting reaction solution, adding a mixture of the first antibody moiety and the second antibody moiety to be connected in an equal volume into the connecting reaction solution, and then resuspending the nanomaterial with the connecting reaction solution containing the first antibody moiety and the second antibody moiety and conducting the connecting reaction for 0.5-5 hours at room temperature. After the reaction, the nanomaterial is collected by centrifugation. The nanomaterial is washed twice in Dulbecco's phosphate buffer saline (D-PBS), and then resuspended in D-PBS and stored at 4° C.
- The method for producing bispecific antibodies described herein comprises the following steps:
- (1) Preparation of nanomaterials: The nanomaterial is completely dissolved in acetone at a concentration of 5 to 30 mg/mL, and the solution of the nanomaterial with acetone is added to the deionized water in 1:4 v/v of acetone and deionized water with magnetic stirred at 500 to 1500 rpm/min, to form a uniform emulsion and then continue to stir until the volatilization of acetone;
(2) Collection of nanomaterials: collecting the prepared nanomaterials by centrifugation at 8000˜15000 rpm/min, and then washing the nanomaterials by resuspending in deionized water twice;
(3) Activation of nanomaterials: activating the nanomaterials by using a mixed solvent of 1-10 mg/mL 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride and N-hydroxysuccinimide at room temperature for 0.5˜5 hours;
(4) Connection of nanomaterials with antibodies: collecting the activated nanomaterials by centrifugation, and then washing the nanomaterials once with 0.1 M D-PBS at pH=8.0, and adding a mixture of the first antibody moiety and the second antibody moiety to be connected in an equal volume into the connecting reaction solution, and then resuspending the nanomaterials with the connecting reaction solution containing the first antibody moiety and the second antibody moiety and conducting the connecting reaction for 0.5-5 hours at room temperature. After the reaction, the nanomaterials are collected by centrifugation. The nanomaterials are washed twice in D-PBS, and then resuspended in D-PBS and stored at 4° C. - In a third aspect, the present invention also provides the use of the bispecific antibody as described in the first aspect in the manufacture of a medicament for the treatment, prevention or diagnosis of a tumor. The tumor includes, but not limited to, liver cancer, non-small cell lung cancer, small cell lung cancer, adrenocortical carcinoma, acute (chronic B) lymphocytoma, myeloma, prostate cancer, breast cancer, esophageal cancer, gastric cancer, colorectal cancer, cervical cancer, kidney cancer, bladder cancer and lymphoma.
- In a fourth aspect, the present invention also provides the bispecific antibody according to any one of
claims 1 to 3 for use in the treatment or prevention of a tumor. The tumor includes, but not limited to, liver cancer, non-small cell lung cancer, small cell lung cancer, adrenocortical carcinoma, acute (chronic B) lymphocytoma, myeloma, prostate cancer, breast cancer, esophageal cancer, gastric cancer, colorectal cancer, cervical cancer, kidney cancer, bladder cancer and lymphoma. - In a fifth aspect, the present invention provides a method of treating a tumor comprising administering to a subject the bispecific antibody of the invention. The tumor includes, but not limited to, liver cancer, non-small cell lung cancer, small cell lung cancer, adrenocortical carcinoma, acute (chronic B) lymphocytoma, myeloma, prostate cancer, breast cancer, esophageal cancer, gastric cancer, colorectal cancer, cervical cancer, kidney cancer, bladder cancer and lymphoma.
- Compared with the prior art, the invention has at least the following beneficial effects:
- (1) The bispecific antibody according to present invention can be more quickly, simply and practically produced as compared to the existing bispecific antibodies which are expressed by biological methods. The bispecific antibody according to present invention can be connected directly to the monoclonal antibodies approved on the market. Because the raw materials to be used are all clinically approved on the market, the bispecific antibody prepared according to the invention can quickly enter clinical use;
(2) Compared with immune cell therapy via the genetically-modified chimeric antigen receptor T cell (CAR-T), the bispecific antibody of the present invention has disadvantages such as biodegradability, no gene recombination, low side effect, high safety, low cost, capability to combine respective specific antibodies for various tumor cells, ease of use, etc. According to present invention, a similar effect on targeting and efficiently killing cancer cells can be achieved by administrating the bispecific antibody preparation of the present invention to a subject while returning the CTL cells induced in vitro to the subject via infusion. The resulted side effects are lower than CAR-T therapy;
(3) All of the materials of the present invention can be degraded into non-toxic and harmless products in the human body and can be degraded and metabolized shortly. Accordingly, the present invention is safer than CAR-T. -
FIG. 1 shows assembling of the bispecific antibody of Example 1. -
FIG. 2 shows the result of the cell killing experiments of the bispecific antibody of Example 1. -
FIGS. 3-9 show the ability of other bispecific antibodies to kill tumor cells. -
FIG. 10 shows the efficacy of a bispecific antibody anti-CD3-PLGA-anti-MUC1 on inhibiting tumor in vivo. -
FIG. 11 shows the curve of laboratory animal mortality for antitumor experiments in vivo. - The invention is described in details through the Examples, with reference to the accompanying drawings.
-
FIG. 1 shows assembling of the bispecific antibody of this Example. The process comprises the following specific steps: - (1) Preparation of PLGA nanoparticles: PLGA was completely dissolved to a concentration of 5 mg/mL using acetone, and the solution of PLGA and acetone was added into deionized water in a volume ratio of 1:4 of acetone and deionized water with magnetic stirring at 1000 rpm/min, to form a uniform emulsion, and then continue to stir until volatilization of acetone;
(2) Collection of PLGA nanoparticles: collecting the prepared nanoparticles with larger particle size by centrifugation at 8000 rpm/min for 10 min; then collecting the prepared nanoparticles with smaller particle size by centrifugation at 15000 rpm/min for 10 min, and then resuspended in deionized water respectively, and repeatedly washing the nanomaterials twice; nanoparticles with larger particle size and nanoparticles with smaller particle size were carried out as follows;
(3) Activation of PLGA nanoparticles: using a mixed solvent of 5 mg/mL 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride and N-hydroxysuccinimide at room temperature to activate PLGA nanopoarticles for 1 h;
(4) Connecting PLGA nanoparticles to antibodies: collecting the activated nanomaterials by centrifugation, and then washing the nanomaterial once with 0.1 M D-PBS at pH=8.0, and adding a mixture of CD3 and Muc1 monoclonal antibodies to be connected in an equal volume into the connecting reaction solution, and then resuspending the nanomaterial with the connecting reaction solution containing the first antibody moiety and the second antibody moiety and conducting the connecting reaction for 0.5 h at room temperature. After the reaction, the nanomaterial is collected by centrifugation. The nanomaterial is washed twice in D-PBS, and then resuspended in D-PBS and stored at 4° C. - The bispecific antibody of Example 1 was added to T cell and cancer cell MCF-7 killing experimental system to detect the ability of the bispecific antibody to enhance the ability of T cell to kill cancer cell, in which T cell: MCF-7=4:1, the reaction time is 8 h, in which the control group is the same amount of nanoparticles (not connected to any antibody). The results are expressed as the average±standard deviation of three independent experiments. The evaluation results are shown in
FIG. 2 , in which * indicates a significant difference in T test. - The A in
FIG. 2 represents bispecific antibodies connected to nanoparticles with a larger particle size (i.e., particles collected by centrifugation at 8000 rpm/min for 10 min), while B represents bispecific antibodies connected to nanoparticles with a smaller particle size (i.e., particles not collected by centrifugation at 8000 rpm/min for 10 min but collected by centrifugation at 15,000 rpm/min for 10 min). - It can be seen from
FIG. 2 that the killing rate of the control group is 7.9%; the killing rate of the group of the bispecific antibodies connected to nanoparticles with a larger particle size is 24.5%; the killing rate of the group of the bispecific antibodies connected to nanoparticles with a smaller particle size is 40.7%. - Using PLA as nanomaterial, bispecific antibodies capable of being combined with immune cells to enhance the targeting tumor killing ability were prepared. The preparation process is as follows:
- (1) Preparation of PLA nanoparticles: PLA was completely dissolved to a concentration of 15 mg/mL using acetone, and the solution of PLA and acetone was added into deionized water in a volume ratio of 1:4 of acetone and deionized water with magnetic stirring at 500 rpm/min, to form a uniform emulsion, and then continue to stir until volatilization of acetone;
(2) Collection of PLA nanoparticles: collecting the prepared nanoparticles by centrifugation at 8000 rpm/min, and then resuspended in deionized water, and repeatedly washing the nanomaterials twice;
(3) Activation of PLA nanoparticles: using a mixed solvent of 1 mg/mL 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride and N-hydroxysuccinimide at room temperature to activate PLA nanopoarticles for 0.5 h;
(4) Connecting PLA nanoparticles to antibodies: collecting the activated nanomaterials by centrifugation, and then washing the nanomaterials once with 0.1 M D-PBS at pH=8.0, and adding a mixture of CD3 and CD19 monoclonal antibodies to be connected in an equal volume into the connecting reaction solution, and then resuspending the nanomaterials with the connecting reaction solution containing the first antibody moiety and the second antibody moiety and conducting the connecting reaction for 5 h at room temperature. After the reaction, the nanomaterials are collected by centrifugation. The nanomaterials are washed twice in D-PBS, and then resuspended in D-PBS and stored at 4° C. - Using PCL as nanomaterials, bispecific antibodies capable of being combined with immune cells to enhance the targeting tumor killing ability was prepared. The preparation process is as follows:
- (1) Preparation of PCL nanoparticles: PCL was completely dissolved to a concentration of 30 mg/mL using acetone, and the solution of PCL and acetone was added into deionized water in a volume ratio of 1:4 of acetone and deionized water with magnetic stirring at 1500 rpm/min, to form a uniform emulsion, and then continue to stir until volatilization of acetone;
(2) Collection of PCL nanoparticles: collecting the prepared nanoparticles by centrifugation at 15000 rpm/min, and then resuspended in deionized water, and repeatedly washing the nanomaterials twice;
(3) Activation of PCL nanoparticles: using a mixed solvent of 10 mg/mL 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride and N-hydroxysuccinimide at room temperature to activate PCL nanopoarticles for 5 h;
(4) Connecting PCL nanoparticles to antibodies: collecting the activated nanomaterials by centrifugation, and then washing the nanomaterials once with 0.1 M D-PBS at pH=8.0, and adding a mixture of CD3 and CD20 monoclonal antibodies to be connected in an equal volume into the connecting reaction solution, and then resuspending the nanomaterials with the connecting reaction solution containing the first antibody moiety and the second antibody moiety and conducting the connecting reaction for 2.5 h at room temperature. After the reaction, the nanomaterials are collected by centrifugation. The nanomaterials are washed twice in D-PBS, and then resuspended in D-PBS and stored at 4° C. - The ability of PLGA-connected anti-CD3 and anti-MUC1 bispecific antibodies (anti-CD3-PLGA-anti-MUC1) to kill other tumor cells was evaluated.
- Specifically, 5000 target cells were cultured in each well for 12 h in 96-well plates and then the original medium was discarded. The density of DC-CIK cells was adjusted by X-vivo 15 medium without cytokine, resulting in that DC-CIK cell number in a volume of 100 μl was 4 times larger than the target cells (effect-target ratio is 4:1). 100 μl suspension of DC-CIK cells was added in a cancer cell culture plate, and 10 μl prepared bispecific antibody (bispecific antibody preparation content: 0.2 mg, with a total amount of monoclonal antibodies 0.2 μg) was added, incubated for 8 h in an incubator, and then CCK-8 reagent was added, incubated according to the reagent instructions. The absorbance at 450 nm was measured using a microplate reader. Statistical analysis of the data was performed, according to the following formula to calculate killing rate of DC-CIK cells on cancer cells.
-
Killing rate=[1−(experimental group−effect control group)/(target control group−blank control group)]×100% - The blank control group represents the added medium; the target control group represents the added target cell+medium; the effect control group represents the added the effector cell+medium; the experimental group represents the effector cell+target cell+medium+bispecific antibody.
- The results are shown in Table 1 and
FIG. 3 . -
TABLE 1 The ability of anti-CD3-PLGA-anti-MUC1 to kill tumor cells Killing rate Cancer cell Effect control group Experimental group HKC 9.66% 13.21% A549 7.59% 87.35% HcpG2 10.67% 82.44% HT29 13.84% 91.27% AGS 17.56% 92.17% Hela 13.57% 87.54% 5637 11.64% 82.51% OS-RC-2 12.24% 87.57% Note: HKC - human embryo kidney epithelial cells; A549 - human non-small cell lung cancer cells; HepG2 - human liver cancer cells; HT29 - human colon cancer cells; AGS - human gastric adenocarcinoma cells; Hela - human cervical cancer cells; 5637 - human bladder cancer cells; OS-RC-2 - human kidney cancer cells. - Using the processes method as described above, with PLGA, PLA or PCL as nanomaterials, anti-CD3 and anti-CD33 bispecific antibodies connected via nanoparticles, i.e. anti-CD3-PLGA-anti-CD33, anti-CD3-PLA-anti-CD33 and anti-CD3-PCL-anti-CD33, were prepared. The ability of the bispecific antibodies of the invention to kill tumor cells was evaluated according to the method described in Example 5.
- The results are shown in Table 2 and
FIG. 4 . -
TABLE 2 The ability of anti-CD3-PLGA-anti-CD33 to kill tumor cells Killing rate Cancer cell Effect control group Experimental group Raji 8.59% 85.91% RAMOS 13.67% 83.36% Note: Raji - black Burkitt lymphoma cells; RAMOS - human B lymphocytoma cells. - The bispecific antibodies CD3-PLA-CD33 and CD3-PCL-CD33 both showed a killing rate of more than 83% for black Burkitt lymphoma cells and human B lymphocytoma cells.
- Using the similar processes as described above, with PLGA, PLA or PCL as nanomaterials, anti-CD8 and anti-MUC1 bispecific antibodies connected via nanoparticles, i.e. anti-CD8-PLGA-anti-MUC1, anti-CD8-PLA-anti-MUC1 and anti-CD8-PCL-anti-MUC1, were prepared. The ability of the bispecific antibodies of the invention to kill tumor cells was evaluated according to the method described in Example 5.
- The results are shown in Table 3 and
FIG. 5 . -
TABLE 3 The ability of anti-CD8-PLGA-anti-MUC1 to kill tumor cells Killing rate Cancer cell Effect control group Experimental group HKC 9.66% 13.21% A549 7.59% 87.35% HepG2 10.67% 82.44% HT29 13.84% 91.27% MCF-7 8.62% 87.23% AGS 17.56% 92.17% Hela 13.57% 87.54% 5637 11.64% 82.51% OS-RC-2 12.24% 87.57% Note: HKC - human embryo kidney epithelial cells; A549 - human non-small cell lung cancer cells; HepG2 - human liver cancer cells; HT29 - human colon cancer cells; AGS - human gastric adenocarcinoma cells; Hela - human cervical cancer cells; 5637 - human bladder cancer cells; OS-RC-2 - human kidney cancer cells. - The bispecific antibodies anti-CD8-PLA-anti-MUC1 and anti-CD8-PCL-anti-MUC1 both showed a killing rate of more than 95% for human non-small cell lung cancer cells and human gastric adenocarcinoma cells; both showed a killing rate of more than 92% for human colon cancer cells and human kidney cancer cells; both showed a killing rate of nearly 90% for human breast cancer cells, human cervical cancer cells and human bladder cancer cells; showed a killing rate of about 80% for human liver cancer cells.
- Using the similar process as described above, other bispecific antibodies connected via nanoparticles, i.e. anti-CD3-PLGA-anti-CD19, anti-CD3-PLGA-anti-CD20, anti-CD3-PLGA-anti-her2 were prepared. The ability of the bispecific antibodies to kill tumor cells was evaluated. The results are shown in Tables 4-7 and
FIGS. 6-9 . -
TABLE 4 The ability of anti-CD3-PLGA-anti-CD19 to kill tumor cells Killing rate Cancer cell Effect control group Experimental group Raji 8.59% 82.91% RAMOS 13.67% 89.36% Note: Raji - black Burkitt lymphoma cells; RAMOS - human B lymphocytoma cells. -
TABLE 5 The ability of anti-CD3-PLGA-anti-CD20 to kill tumor cells Killing rate Cancer cell Effect control group Experimental group Raji 8.59% 92.71% RAMOS 13.67% 88.27% Note: Raji - black Burkitt lymphoma cells; RAMOS - human B lymphocytoma cells. -
TABLE 6 The ability of anti-CD3-PLGA-anti-her2 to kill tumor cells Killing rate Cancer cell Effect control group Experimental group MCF-7 19.88% 63.84% Note: MCF-7 - human breast cancer cells. -
TABLE 7 The ability of anti-CD3-PLGA-anti-CD38 to kill tumor cells Killing rate Cancer cell Effect control group Experimental group Raji 28.55% 87.78% Note: Raji - black Burkitt lymphoma cells. - The anti-tumor effect of the bispecific antibodies of the present invention were evaluated. Specifically, healthy Balb-c nude mice (clean grade, female, four weeks old, 18-22 g in weight, purchased from the Guangdong Provincial Medicine Laboratory Animal Center) were inoculated with human lung adenocarcinoma cell A549 at armpit. After 3-4 weeks of inoculation, 30 nude mice with tumor diameter of about 0.5×0.5 cm were randomly divided into three groups for the experiment.
- At the time of
day 1, 3, 5, all mice were administered once via the tail-intravenous injection. 1×106 DC-CIK cells were injected each time in the DC-CIK group; 1×106 DC-CIK cells and 0.4 mg (a total amount of monoclonal antibody 0.4 μg) bispecific antibody anti-CD3-PLGA-anti-MUC1 were each time injected in the DC-CIK+bispecific antibody group; the same volume of saline was injected in the control group. - The tumor volume was recorded from the first day. Calculate the inhibitory rate of the bispecific antibodies against tumors.
- After the death of all the animals in the control group and the DC-CIK alone treatment group, the experiment was terminated. The total time of observation was 128 days.
- The average tumor volume of each group is shown in
FIG. 10 . The results showed that the inhibitory rate of the bispecific antibody anti-CD3-PLGA-anti-MUC1 against tumors was 88.73%, and the tumors of 60% of the animals (6/10) completely disappeared. - In terms of survival time, treatment with DC-CIK alone and treatment with DC-CIK+bispecific antibody both provided significant survival benefit when compared to untreated mice (
FIG. 11 ). All the untreated mice died before day 105. All mice in the DC-CIK only treatment group died before day 128, while 6 mice still survived in the DC-CIK+bispecific antibody treatment group. - As can be seen from the above Examples, the bispecific antibodies of the present invention have an improved ability to kill cancer cells by T cells, can be combined with the immune cells to enhance tumor killing ability, and have advantages such as less side effects, higher safety, lower cost, easy to use and so on as compared to CAR-T immune cell therapy.
- The Applicant declares that the present invention illustrates the processes of the present invention via the above-described Examples, but the invention is not limited to the above-described process steps, i.e. it is not meant that the present invention must be carried out in accordance with the above-described process steps. It will be apparent to those skilled in the art that any improvements to the present invention, equivalents of the materials selected for use in the present invention, addition of auxiliary ingredients, selection of specific ways, etc., are within the disclosure and protection scope of the present invention without departing from the idea, spirit and scope of the invention.
Claims (17)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/935,679 US20200345854A1 (en) | 2015-04-14 | 2020-07-22 | Bispecific antibody capable of being combined with immune cells to enhance tumor killing capability, and preparation method therefor and application thereof |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510175130.3A CN104829730A (en) | 2015-04-14 | 2015-04-14 | Bispecific antibody capable of combining immune cells to enhance tumor killing ability, preparation method and applications thereof |
CN201510175130.3 | 2015-04-14 | ||
PCT/CN2016/079307 WO2016165632A1 (en) | 2015-04-14 | 2016-04-14 | Bispecific antibody capable of being combined with immune cells to enhance tumor killing capability, and preparation method therefor and application thereof |
US201715548630A | 2017-08-03 | 2017-08-03 | |
US16/935,679 US20200345854A1 (en) | 2015-04-14 | 2020-07-22 | Bispecific antibody capable of being combined with immune cells to enhance tumor killing capability, and preparation method therefor and application thereof |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2016/079307 Continuation WO2016165632A1 (en) | 2015-04-14 | 2016-04-14 | Bispecific antibody capable of being combined with immune cells to enhance tumor killing capability, and preparation method therefor and application thereof |
US15/548,630 Continuation US10758625B2 (en) | 2015-04-14 | 2016-04-14 | Bispecific antibody capable of being combined with immune cells to enhance tumor killing capability, and preparation method therefor and application thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
US20200345854A1 true US20200345854A1 (en) | 2020-11-05 |
Family
ID=53807955
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/548,630 Active 2037-03-08 US10758625B2 (en) | 2015-04-14 | 2016-04-14 | Bispecific antibody capable of being combined with immune cells to enhance tumor killing capability, and preparation method therefor and application thereof |
US16/935,679 Pending US20200345854A1 (en) | 2015-04-14 | 2020-07-22 | Bispecific antibody capable of being combined with immune cells to enhance tumor killing capability, and preparation method therefor and application thereof |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/548,630 Active 2037-03-08 US10758625B2 (en) | 2015-04-14 | 2016-04-14 | Bispecific antibody capable of being combined with immune cells to enhance tumor killing capability, and preparation method therefor and application thereof |
Country Status (6)
Country | Link |
---|---|
US (2) | US10758625B2 (en) |
EP (2) | EP4385572A2 (en) |
CN (5) | CN104829730A (en) |
HK (1) | HK1251594A1 (en) |
MA (1) | MA41994A (en) |
WO (2) | WO2016165302A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11464874B2 (en) * | 2016-08-02 | 2022-10-11 | Memorial Sloan-Kettering Cancer Center | Treating metastatic cancer and model systems for metastatic disease |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104829730A (en) * | 2015-04-14 | 2015-08-12 | 苏静 | Bispecific antibody capable of combining immune cells to enhance tumor killing ability, preparation method and applications thereof |
US11000603B2 (en) | 2015-04-14 | 2021-05-11 | Benhealth Biopharmaceutic (Shenzhen) Co., Ltd. | Multi-specific binding conjugate, related pharmaceutical compositions and use |
CN104826110B (en) * | 2015-05-19 | 2017-09-29 | 中国人民解放军第二军医大学 | The preparation and its synergistic treatment application of multipurpose antibody nanocluster of new generation |
CN109824778B (en) * | 2015-09-18 | 2022-07-19 | 上海科济制药有限公司 | anti-CD 19 fully human antibodies and immune effector cells targeting CD19 |
US20190000989A1 (en) * | 2016-01-11 | 2019-01-03 | STC Biologics Inc. | Bispecific targeting agents and methods for their preparation |
CN109195992A (en) * | 2016-04-29 | 2019-01-11 | 本康生物制药(深圳)有限公司 | Polyspecific combination conjugate, relevant pharmaceutical composition and application |
WO2017219974A1 (en) * | 2016-06-22 | 2017-12-28 | 本康生物制药(深圳)有限公司 | Bispecific antibody and antibody conjugate for tumour therapy and use thereof |
WO2018137609A1 (en) * | 2017-01-24 | 2018-08-02 | 本康生物制药(深圳)有限公司 | Antibody conjugate, and related pharmaceutical composition and application |
CN110520442A (en) * | 2017-03-17 | 2019-11-29 | 本康生物制药(深圳)有限公司 | Multi-specificity antibody, antibody coupling matter and relevant pharmaceutical composition and application |
CN107177632B (en) * | 2017-05-27 | 2020-02-07 | 上海优卡迪生物医药科技有限公司 | OCTS technology-based myeloid leukemia CAR-T treatment vector and construction method and application thereof |
TW201925782A (en) * | 2017-11-30 | 2019-07-01 | 瑞士商諾華公司 | BCMA-targeting chimeric antigen receptor, and uses thereof |
AU2019281019A1 (en) * | 2018-06-07 | 2020-11-26 | Oncoone Research & Development Gmbh | Anti-oxMIF/anti-CD3 antibody for cancer treatment |
CN110687293A (en) * | 2018-07-06 | 2020-01-14 | 中国人民解放军第四军医大学 | Kit for detecting gastric cancer antigen MG7-Ag and application thereof |
CN112469734A (en) * | 2018-08-03 | 2021-03-09 | 南京驯鹿医疗技术有限公司 | T cell expressing chimeric antigen receptor, expression vector related to chimeric antigen and application of T cell and expression vector |
US20210403575A1 (en) * | 2018-10-22 | 2021-12-30 | Shanghai Yichen Biomed Co. Ltd | Bispecific antibody |
CA3117079A1 (en) * | 2018-10-30 | 2020-05-07 | Peter Maccallum Cancer Institute | Bispecific polypeptides for engagement of car expressing immune cells with antigen presenting cells and uses thereof |
KR102437436B1 (en) * | 2019-04-26 | 2022-08-30 | 주식회사 엠디헬스케어 | Proteins derived from Streptococcus pyogenes bacteria and Use thereof |
CN110123844A (en) * | 2019-05-13 | 2019-08-16 | 天津大学 | The synthetic method of the tumor combined therapeutic nanometer formulation of CuS mineralising influenza virus |
WO2021030586A1 (en) * | 2019-08-15 | 2021-02-18 | City Of Hope | Dual bispecific antibody compounds and uses thereof |
CN116859051A (en) * | 2019-12-31 | 2023-10-10 | 科美博阳诊断技术(上海)有限公司 | Homogeneous detection kit for interleukin 6 and application thereof |
CN112336873B (en) * | 2020-08-04 | 2022-04-19 | 华南理工大学 | Protein type nanoparticle for multi-specific antibody delivery and application and preparation method thereof |
WO2022063302A1 (en) * | 2020-09-25 | 2022-03-31 | 克莱格医学有限公司 | Regulation of immune cell activity |
JP2023550148A (en) | 2020-11-20 | 2023-11-30 | シンシア・イノベーション・インコーポレイテッド | Armed dual CAR-T compositions and methods used in cancer immunotherapy |
WO2022148736A1 (en) | 2021-01-05 | 2022-07-14 | Transgene | Vectorization of muc1 t cell engager |
CN112807447A (en) * | 2021-01-18 | 2021-05-18 | 中国药科大学 | PD-L1 targeted sorafenib-loaded PLGA nano preparation and preparation method thereof |
CN114085376B (en) * | 2021-12-02 | 2022-12-20 | 中国科学院长春应用化学研究所 | Polypeptide, preparation method thereof, bispecific antibody and application thereof |
WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
CN116789828B (en) * | 2023-05-31 | 2023-11-17 | 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) | anti-CD 132 monoclonal antibody and application thereof |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7829064B2 (en) * | 1999-05-10 | 2010-11-09 | Immunomedics, Inc. | Anti-CD74 immunoconjugates and methods |
CN1470289A (en) * | 2002-07-26 | 2004-01-28 | 北京华京五方实用纳米科技开发有限公 | Polymeric nano medicine carrier and preparation preparing method |
EP1740946B1 (en) | 2004-04-20 | 2013-11-06 | Genmab A/S | Human monoclonal antibodies against cd20 |
CN105709237A (en) * | 2005-12-16 | 2016-06-29 | Ibc 医药公司 | Multivalent immunoglobulin-based bioactive assemblies |
US9315567B2 (en) * | 2012-08-14 | 2016-04-19 | Ibc Pharmaceuticals, Inc. | T-cell redirecting bispecific antibodies for treatment of disease |
US9682143B2 (en) * | 2012-08-14 | 2017-06-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
CA2892059C (en) * | 2012-11-21 | 2023-02-14 | Wuhan Yzy Biopharma Co., Ltd. | Bispecific antibody |
CN107753954A (en) * | 2012-12-13 | 2018-03-06 | 免疫医疗公司 | The dosage of the antibody that effect is improved and toxicity reduces and SN 38 immunoconjugates |
EP2943565B1 (en) * | 2013-01-14 | 2018-03-28 | Fred Hutchinson Cancer Research Center | Compositions and methods for delivery of immune cells to treat un-resectable or non-resected tumor cells and tumor relapse |
US10351626B2 (en) * | 2013-03-14 | 2019-07-16 | The Scripps Research Institute | Targeting agent antibody conjugates and uses thereof |
WO2015035365A1 (en) * | 2013-09-09 | 2015-03-12 | The Nohns Hopkins University | Targeting the m2-tumor associated macrophage for cancer therapy |
CN104829730A (en) * | 2015-04-14 | 2015-08-12 | 苏静 | Bispecific antibody capable of combining immune cells to enhance tumor killing ability, preparation method and applications thereof |
WO2017219974A1 (en) | 2016-06-22 | 2017-12-28 | 本康生物制药(深圳)有限公司 | Bispecific antibody and antibody conjugate for tumour therapy and use thereof |
-
2015
- 2015-04-14 CN CN201510175130.3A patent/CN104829730A/en active Pending
- 2015-10-20 WO PCT/CN2015/092339 patent/WO2016165302A1/en active Application Filing
-
2016
- 2016-04-14 EP EP24172423.6A patent/EP4385572A2/en active Pending
- 2016-04-14 EP EP16779607.7A patent/EP3290440B1/en active Active
- 2016-04-14 WO PCT/CN2016/079307 patent/WO2016165632A1/en active Application Filing
- 2016-04-14 CN CN202110322831.0A patent/CN113292654A/en active Pending
- 2016-04-14 CN CN201680020916.0A patent/CN107531790A/en active Pending
- 2016-04-14 US US15/548,630 patent/US10758625B2/en active Active
- 2016-04-14 CN CN202010918971.XA patent/CN112430270A/en active Pending
- 2016-04-14 MA MA041994A patent/MA41994A/en unknown
- 2016-04-14 CN CN202110323237.3A patent/CN113214401A/en active Pending
-
2018
- 2018-08-31 HK HK18111181.6A patent/HK1251594A1/en unknown
-
2020
- 2020-07-22 US US16/935,679 patent/US20200345854A1/en active Pending
Non-Patent Citations (1)
Title |
---|
Chen et al., PLGA-nanoparticle mediated delivery of anti-OX40 monoclonal antibody enhances anti-tumor cytotoxic T cell responses, Cellular Immunology, 287 (2014), 91-99, Publication Date: 2014-01-13 (Year: 2014) * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11464874B2 (en) * | 2016-08-02 | 2022-10-11 | Memorial Sloan-Kettering Cancer Center | Treating metastatic cancer and model systems for metastatic disease |
US12059480B2 (en) | 2016-08-02 | 2024-08-13 | Memorial Sloan-Kettering Cancer Center | Treating metastatic cancer and model systems for metastatic disease |
Also Published As
Publication number | Publication date |
---|---|
CN112430270A (en) | 2021-03-02 |
MA41994A (en) | 2018-03-07 |
WO2016165632A1 (en) | 2016-10-20 |
EP3290440A1 (en) | 2018-03-07 |
CN107531790A (en) | 2018-01-02 |
EP4385572A2 (en) | 2024-06-19 |
EP3290440B1 (en) | 2024-05-15 |
EP3290440A4 (en) | 2018-12-12 |
WO2016165302A1 (en) | 2016-10-20 |
US10758625B2 (en) | 2020-09-01 |
HK1251594A1 (en) | 2019-02-01 |
CN113214401A (en) | 2021-08-06 |
CN104829730A (en) | 2015-08-12 |
US20180021440A1 (en) | 2018-01-25 |
CN113292654A (en) | 2021-08-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20200345854A1 (en) | Bispecific antibody capable of being combined with immune cells to enhance tumor killing capability, and preparation method therefor and application thereof | |
EP3450460B1 (en) | Multi-specific binding conjugate, related pharmaceutical compositions and use | |
CN107735090B (en) | antibody-SN-38 immunoconjugates with CL2A linkers | |
US20210338836A1 (en) | Multi-specific binding conjugate, related pharmaceutical compositions and use | |
JP6980980B2 (en) | The combination of anti-HLA-DR or anti-TROP-2 antibodies with microtubule inhibitors, PARP inhibitors, Breton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves the therapeutic effect of cancer. | |
JP6427789B2 (en) | Antibody-SN-38 immune complex with CL2A linker | |
JP2020183429A (en) | Administration of immunoconjugates comprising antibody and sn-38 for improving efficacy and reducing toxicity | |
CN107708741A (en) | The physics carried out with the T cell (CAR T) or NK cells (CAR NK) of Chimeric antigen receptor (CAR) construct and expression CAR constructs | |
JP2016513098A (en) | An extremely potent prodrug form of 2-pyrrolinodoxorubicin (P2PDOX) conjugated with an antibody for cancer targeted therapy | |
JP2016535009A (en) | Methods of antibody-dependent exosome therapy | |
JP2008523083A (en) | Methods and compositions for immunotherapy and detection of inflammatory and immune dysregulated diseases, infectious diseases, pathological angiogenesis and cancer | |
CN103501825A (en) | Ultrafiltration concentration of allotype selected antibodies for small-volume administration | |
TW202118518A (en) | Compositions and methods for local and systemic treatment of cancers, tumors and tumor cells | |
WO2021104414A1 (en) | Method for coupling antibodies on cell surface and application thereof | |
CN110248680A (en) | The therapy for metastatic bladder transitional cell carcinoma of health (IMMU-132) is replaced using the husky western trastuzumab dagger-axe dimension of antibody-drug conjugates | |
CN109562172A (en) | The effect of anti-HLA-DR antibody drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancer | |
WO2023024949A1 (en) | Antibody-drug conjugate conjugated via breakable linker | |
EP3599250A1 (en) | Antibody conjugate, and related pharmaceutical composition and application | |
WO2023103854A1 (en) | Antibody-drug conjugate having improved affinity, and preparation method therefor and application thereof | |
ES2886927T3 (en) | Immunoconjugates of antibody-SN-38 with a CL2A linker | |
JP2023508624A (en) | Methods and compositions for cancer treatment using nanoparticles conjugated with multiple ligands to bind receptors on NK cells | |
WO2024079592A1 (en) | Genetically engineered anti-cd19 car-t cells for use in treating b-cell malignancies |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE AFTER FINAL ACTION FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: ADVISORY ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: ADVISORY ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |